INVO Bioscience, Inc.
INVOTicker | Value | Shares | Price | Security | Type | Insider | Title | Return | Flags | Date |
|---|---|---|---|---|---|---|---|---|---|---|
| No transactions found | ||||||||||
Insider trading at INVO Bioscience, Inc. (INVO) refers to stock transactions executed by corporate insiders—officers, directors, and shareholders owning more than 10% of the company. Over the past 90 days, 10 insiders have filed 43 transactions totaling $961.1K in trading activity. The most active insider is Investment Company, Inc. Awm (Executive), contributing $424.2K across 14 transactions.
INVO Bioscience, Inc. insiders are currently net buyers of INVO stock, showing bullish sentiment over the past 90 days. Executives have purchased $961.1K while selling $0, resulting in a positive net flow of $961.1K. This buying activity represents 100% of total transaction volume.
INVO Bioscience, Inc. has 10 active insiders who have filed SEC Form 4 transactions in the past 90 days. Investment Company, Inc. Awm (Executive) leads with 14 transactions totaling $424.2K. Kevin Doody (Executive) follows with 3 transactions worth $168.4K. Open-market purchases require insiders to invest their own capital, demonstrating genuine conviction.
The Insider Alignment Score measures the ratio of buying to selling activity on a 0-100 scale. INVO Bioscience, Inc.'s current score of 100/100 indicates bullish insider sentiment. Scores above 60 suggest insiders are accumulating shares faster than selling, reflecting $961.1K in purchases versus $0 in sales.
The most recent insider transaction occurred on Jun 1, 2022, when Doody Kevin (Executive) acquired 177,306 shares at $0.95 per share for $168.4K. This appears to be a discretionary trade.
Based on SEC Form 4 filings from the past 90 days, INVO insider trading sentiment is currently bullish with an Alignment Score of 100/100. The net insider flow of $961.1K reflects accumulation, with 100% of volume being purchases.
SEC Form 4 is the primary disclosure mechanism for insider trading at publicly traded companies like INVO Bioscience, Inc.. Corporate insiders must file within two business days of any transaction, making it one of the most timely sources of executive sentiment. At INVO, we track all Form 4 filings—currently showing 43 transactions from 10 insiders over 90 days.
A 10b5-1 plan allows INVO Bioscience, Inc. executives to pre-schedule stock sales when they don't possess material non-public information. At INVO, approximately 0% of recent transactions are 10b5-1 trades. Most trading activity at INVO appears discretionary, making insider signals more meaningful.
You can monitor INVO Bioscience, Inc. (INVO) insider trading activity on this page, which updates within hours of new SEC Form 4 filings. We track all 10 active insiders and provide real-time transaction feeds, the Alignment Score, 10b5-1 vs. discretionary breakdowns, and direct links to SEC EDGAR filings.
Insider trading at INVO Bioscience, Inc. (INVO) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of shares. These individuals must report trades to the SEC within two business days. Currently, 10 insiders are actively trading INVO stock, having executed 43 transactions in the past 90 days. The most active insider is Investment Company, Inc. Awm (Executive), with 14 transactions totaling $424.2K.
Our Alignment Score measures the ratio of insider buying to selling on a scale of 0-100. A score above 70 indicates strong bullish sentiment, while below 30 suggests bearish activity. INVO Bioscience, Inc.'s current score of 100/100 indicates strong bullish sentiment with executives accumulating shares. This is calculated from $961.1K in purchases versus $0 in sales over 90 days, resulting in a net flow of $961.1K.
SEC Form 4 filings are mandatory reports that INVO Bioscience, Inc. insiders must submit within 2 business days. Each filing includes the insider's name, relationship, transaction type, shares, and price. Transaction codes: P (purchase), S (sale), A (award), M (option exercise), G (gift). At INVO, the most common type is "P" with 25 occurrences. The most recent Form 4 was filed on Jun 1, 2022 by Doody Kevin.
Rule 10b5-1 allows corporate insiders to establish pre-scheduled trading plans when they don't possess material non-public information. At INVO Bioscience, Inc., approximately 0% of recent transactions are executed under 10b5-1 plans, while 100% appear to be discretionary trades. The low percentage means most insider activity at INVO represents discretionary decisions with more informational value.
Track every insider move.
Before the market reacts.
Set alerts for INVO Bioscience, Inc. and 40,000+ other insiders.